Taken together, these data illustrate that combination therapy of a PIKfyve inhibitor and MEK inhibitor eliminated tumor burden in an immunocompetent orthotopic PDAC model (Extended Data Fig. 11C). The gene discussed is MAP2K7; the disease is neoplasm.